We describe an HLA matched bone marrow transplantation with minor ABO incompatibility and RhD mismatch (donor RhD negative and recipient RhD positive). GVHD appeared on day +96 and therapy with steroid and cyclosporin was started. When GVHD disappeared and immunosuppressive therapy was stopped (2 years after BMT), an anti-RhD antibody was detected in the patient's serum. The delayed appearance of this antibody may have been associated with the prolonged immunosuppression that was required for treatment of the patient's GVHD. Bone Marrow Transplantation (2000) 25, 457-459. Keywords: bone marrow transplantation; anti-RhD alloantibody; GVHD A 23-year-old female patient with ALL (NULL phenotype), in complete remission following chemotherapy, underwent allogeneic BMT from her HLA-identical brother in 1995. His pretransplant RBC phenotype was A CcDee whereas the donor was O ccdee. The pretransplant immunohematological studies (indirect antiglobulin test: IAT and direct antiglobulin test: DAT) were negative both in donor and in recipient.
A 23-year-old female patient with ALL (NULL phenotype), in complete remission following chemotherapy, underwent allogeneic BMT from her HLA-identical brother in 1995. His pretransplant RBC phenotype was A CcDee whereas the donor was O ccdee. The pretransplant immunohematological studies (indirect antiglobulin test: IAT and direct antiglobulin test: DAT) were negative both in donor and in recipient.
The conditioning therapy with hyperfractioned TBI and high-dose CY was started in January 1995. Two days after chemotherapy, 1200 ml of bone marrow (containing 3.8 × 10 8 nucleated cells/kg recipient) were collected from the donor's iliac crests. Plasma was removed from the donor bone marrow because of the minor ABO incompatibility: the final volume (515 ml) was then reinfused into the recipient through a central venous catheter. On the day before BMT, the patient was started on acute GVHD prophylaxis with i.v. cyclosporin (3 mg/kg once daily) until day +15 and continued p.o. (initial dosage 6 mg/kg every 12 h, then adjusted to blood levels). During the aplastic period the patient was transfused with 2 units of group O Rh-negative RBC and 4 units of single donor platelets Correspondence: Dr G Gandini, Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, 37134 Verona, Italy Received 2 August 1999; accepted 14 October 1999 (group A). All blood products were irradiated with 24 Gy and filtered. On day +12 bone marrow aspirate and laboratory tests (platelets Ͼ20 × 10 9 /l and granulocytes Ͼ0.5 × 10 9 /l) confirmed engraftment. Bone marrow and blood variable number tandem repeat (VNTR) by PCR revealed the presence of 100% donor cells. On day +20 the patient was discharged and follow-up continued as an outpatient. On discharge there were no signs of acute GVHD; DAT and IAT were negative and RBC ABO grouping test showed the presence of two RBC populations: group A from the recipient and group O from donor and transfusions. The Rh phenotype also showed the presence of two RBC populations, D and C positive, and D and C negative. Serum ABO grouping test showed agglutination only with B RBC (anti-B titer 16). These results were unchanged until day +60. By day +90, recipient RBC had disappeared: ABO blood group and Rh phenotype were O ccdee. DAT and IAT were persistently negative.
On day +96 the patient was re-admitted for acute grade III GVHD with fever, maculopapular rash (60% of total body area) and diarrhea (Ͼ1500 ml/day). Intravenous cyclosporin (3 mg/kg once daily) was started again together with methylprednisolone (2 mg/kg once daily i.v.). Skin and intestinal symptoms faded after a few days and the patient was discharged on oral cyclosporin (initial dosage 6 mg/kg every 12 h, then adjusted to blood levels) and prednisone (1 mg/kg p.o. in two divided doses) 2 weeks later. Red blood cell ABO grouping test, Rh phenotype, IAT and DAT were similar to previous control parameters. Steroid therapy was tapered off by day +170.
On day +189, the patient was admitted again for grade III GVHD with fever, diarrhea with abdominal pain and a widespread itchy rash. Intravenous steroid (methylprednisolone 2 mg/kg once daily) and cyclosporin therapy (3 mg/kg) was restarted. The patient was also given 6 units of filtered and irradiated RBC (O ccdee). After an initial improvement, the skin rash worsened and liver involvement (a rise in bilirubin and hepatic enzymes) appeared. Considering the time elapsed since the BMT, the hepatic involvement and skin biopsy, which were confirmed as chronic GVHD, the patient was started on chronic GVHD therapy with oral cyclosporin (6 mg/kg every 12 h) and prednisone (1 mg/kg) on alternate days. There was a gradual skin and hepatic improvement and the patient was discharged on day +230. Indirect antiglobulin test and DAT Single donor platelets 4 units from day -----+2 to day +20 mf = mixed field agglutination. GVHD therapy from day +96 to day +170 and from day +189 to day +470.
were negative and the ABO blood group and Rh phenotype were O ccdee. The patient underwent monthly check-ups which confirmed that GVHD had disappeared. Prednisone was gradually reduced and stopped on day +470 (May 1996). Cyclosporin therapy was also stopped 2 months later (day +530).
In January 1997, 2 years after BMT, an anti-RhD antibody (IgG class), titer 1:128, was detected in the patient's serum. Direct antiglobulin test was negative, ABO blood group and Rh phenotype were unchanged and bone marrow and blood VNTR confirmed the presence of 100% donor cells. There were no clinical or laboratory signs of hemolysis.
Further tests 2 months later confirmed the presence of the antibody, with raised titer (1:512), which is still present, with the same titer, at last check-up in July 1999. Table 1 summarizes the post-transplant follow-up.
Discussion
Rh mismatch has different features from ABO mismatch. In fact, as the alloantibody anti-RhD does not occur naturally, we talk about major or minor RhD incompatibility only when recipient or donor have antibodies following a previous exposure (eg pregnancy and/or transfusions).
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Like ABO incompatibility, RhD incompatibility can also cause hemolytic anemia after BMT. [2] [3] [4] An RhD positive bone marrow recipient may develop anti-RhD antibodies following transplant if the donor is RhD negative. The recipient's residual RBC may be sufficiently numerous to stimulate the donor's engrafted lymphocytes. 5 This event occurs only rarely however because the donor-related primary immune response usually starts about 6 months after BMT. [6] [7] [8] [9] [10] We report the case of an RhD positive BMT recipient who received RhD negative donor bone marrow and who went on to develop an anti-RhD antibody. The unusual feature of this event is that the antibody produced by the donor's engrafted lymphocytes occurred 2 years after sensitization. Immunization probably came about in the first few months following BMT when residual RhD positive recipient RBC were still present. Other likely causes of immunization were excluded since the patient had only received RhD negative RBC and single donor platelets and she had never had pregnancies. Furthermore, since day +20 bone marrow and blood VNTR revealed the presence of 100% donor cells and no residual RhD positive recipient RBC were detected after day +90.
The delayed appearance of this antibody may be due to the GVHD and subsequent immunosuppressive therapy which slowed down the reconstruction of the engrafted immune system. It is well known that GVHD, expecially when it is chronic, leads to impaired B and T lymphocyte function. Once the GVHD had cleared up and immunosuppressive therapy stopped, the engrafted immune system matured and the co-operation between immunized T lymphocytes and B lymphocytes led to the production of the anti-RhD antibody.
Our report underlines how important it is in such patients to carry out prolonged immunohematological follow-up tests.
